European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
Details
Serval ID
serval:BIB_82EE065BEEA5
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
Journal
Journal of thoracic oncology
Working group(s)
ETOP Mesoscape and ESTS Consortia
Contributor(s)
Stahel R., Hiltbrunner A., Kammler R., Marti N., Ruepp B., Dafni U., Tsourti Z., Zygoura P., Vervita K., Dimopoulou G., Andriakopoulou C., Stavrou A., Rüschoff J.H., Haberecker M., Dettwiler S., Prutek F., Mittmann C., Opitz I., Vrugt B., Friess M., Matter A., Spichiger-Häusermann C., Kirschner M.B., Felley-Bosco E., Baas P., Monkhorst K., Nackaerts K., Verbeken E., Weynand B., Nafteux P., Moons J., Peeters L., Ampollini L., Tiseo M., Silini E.M., Gnetti L., Carbognani P., de Perrot M., Bavaghar-Zaeimi F., Brcic L., Samarzija M., Seiwerth S., Jakopovic M., Nadal E., Cardenal F., Llatjos R., Lorente S., Syrigos K., Vamvakaris I., Tsimpoukis S., Boura P., Gray S.G., Finn S.P., Nur M.M., Baird A.M., Barr M.P., Cuffe S., Gately K., Aerts J., Thüsen J.V., Bille A., Passani S., Brunelli A.
ISSN
1556-1380 (Electronic)
ISSN-L
1556-0864
Publication state
Published
Issued date
09/2023
Peer-reviewed
Oui
Volume
18
Number
9
Pages
1233-1247
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
Pleural mesothelioma (PM) is an aggressive malignancy with increasing prevalence and poor prognosis. Real-life data are a unique approach to reflect the reality of PM epidemiology, treatment, and prognosis in Europe.
A joint analysis of the European Thoracic Oncology Platform Mesoscape and the European Society of Thoracic Surgeons (ESTS) databases was performed to better understand the characteristics and epidemiology of PM, including histologic subtype, staging, and treatment. Overall survival (OS) was assessed, adjusting for parameters of clinical interest.
The analysis included 2766 patients (Mesoscape: 497/10 centers/ESTS: 2269/77 centers). The primary histologic subtype was epithelioid (71%), with 57% patients on stages III to IV. Within Mesoscape, the patients received either multimodality (59%) or palliative intention treatment (41%). The median follow-up was 47.2 months, on the basis of 1103 patients (Mesoscape: 491/ESTS: 612), with 823 deaths, and median OS was 17.4 months. In multivariable analysis, female sex, epithelioid subtype, and lower stage were associated with longer OS, when stratifying by cohort, age, and Eastern Cooperative Oncology Group Performance Status. Within Mesoscape, multimodality treatment including surgery was predictive of longer OS (hazard ratio = 0.56, 95% confidence interval: 0.45-0.69), adjusting for sex, histologic subtype, and Eastern Cooperative Oncology Group Performance Status. Overall, surgical candidates with a macroscopic complete resection had a significantly longer median OS compared with patients with R2 (25.2 m versus 16.4 m; log-rank p < 0.001).
This combined European Thoracic Oncology Platform/ESTS database analysis offers one of the largest databases with detailed clinical and pathologic outcome. Our finding reflects a benefit for selected patients that undergo multimodality treatment, including macroscopic complete resection, and represents a valuable resource to inform the epidemiology and treatment options for individual patients.
A joint analysis of the European Thoracic Oncology Platform Mesoscape and the European Society of Thoracic Surgeons (ESTS) databases was performed to better understand the characteristics and epidemiology of PM, including histologic subtype, staging, and treatment. Overall survival (OS) was assessed, adjusting for parameters of clinical interest.
The analysis included 2766 patients (Mesoscape: 497/10 centers/ESTS: 2269/77 centers). The primary histologic subtype was epithelioid (71%), with 57% patients on stages III to IV. Within Mesoscape, the patients received either multimodality (59%) or palliative intention treatment (41%). The median follow-up was 47.2 months, on the basis of 1103 patients (Mesoscape: 491/ESTS: 612), with 823 deaths, and median OS was 17.4 months. In multivariable analysis, female sex, epithelioid subtype, and lower stage were associated with longer OS, when stratifying by cohort, age, and Eastern Cooperative Oncology Group Performance Status. Within Mesoscape, multimodality treatment including surgery was predictive of longer OS (hazard ratio = 0.56, 95% confidence interval: 0.45-0.69), adjusting for sex, histologic subtype, and Eastern Cooperative Oncology Group Performance Status. Overall, surgical candidates with a macroscopic complete resection had a significantly longer median OS compared with patients with R2 (25.2 m versus 16.4 m; log-rank p < 0.001).
This combined European Thoracic Oncology Platform/ESTS database analysis offers one of the largest databases with detailed clinical and pathologic outcome. Our finding reflects a benefit for selected patients that undergo multimodality treatment, including macroscopic complete resection, and represents a valuable resource to inform the epidemiology and treatment options for individual patients.
Keywords
Humans, Female, Thoracic Surgery, Lung Neoplasms/epidemiology, Lung Neoplasms/surgery, Mesothelioma, Malignant, Mesothelioma/epidemiology, Mesothelioma/surgery, Pleural Neoplasms/epidemiology, Pleural Neoplasms/surgery, Epidemiology, MCR, Multimodality treatment, Pleural mesothelioma, Real-world data, Registry
Pubmed
Web of science
Create date
29/06/2023 14:21
Last modification date
09/12/2023 7:04
Usage data
